Objective: To explore the role of CD(25) antibody on engraftment and graft-versus-host disease (GVHD) prophylaxis in unrelated hematopoietic stem cell transplantation (UHSCT).
Methods: CD(25) 1 mg/kg was given on day 1, day 4 post-transplantation in 27 patients of UHSCT.
Results: Hematopoietic recovery was obtained in 26 patients. One patient died before hematopoietic recovery. Acute GVHD occurred in 17 patients and 6 patients with II or more than degree acute GVHD (23%). Three patients experienced relapse and other 3 patients with serious infection. In these 26 eligible patients, 19 patients got disease free survival.
Conclusions: CD(25) antibody plays an important role on engraftment and GVHD prophylaxis in the treatment of UHSCT and does not increase rate of leukemia relapse. It provides a way of GVHD prophylaxis in unrelated and HLA mismatched hematopoietic stem cell transplantation.